Cosciens Biopharma Inc. posts $1.7 million revenue and $5.9 million net loss for Q3 2025
I'm PortAI, I can summarize articles.
Cosciens Biopharma Inc. reported Q3 2025 revenue of $1.7 million, a significant increase from $0.2 million in the same period last year. The company incurred a net loss of $5.9 million, with research and development expenses decreasing to $0.6 million. Cash and cash equivalents were $8.5 million as of September 30, 2025, down from $16.4 million at the end of 2024. The company continues to develop products in the cosmeceutical, nutraceutical, and pharmaceutical sectors using its PGX technology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments